Morgan Stanley’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $434K | Sell |
93,475
-10,930
| -10% | -$28.3K | ﹤0.01% | 5612 |
|
|
2026
Q1 | $291K | Sell |
104,405
-174,883
| -63% | -$532K | ﹤0.01% | 5708 |
|
|
2025
Q4 | $1.16M | Buy |
279,288
+50,953
| +22% | +$268K | ﹤0.01% | 5102 |
|
|
2025
Q3 | $967K | Buy |
228,335
+19,712
| +9% | +$74.2K | ﹤0.01% | 5192 |
|
|
2025
Q2 | $440K | Sell |
208,623
-36,469
| -15% | -$54.6K | ﹤0.01% | 5527 |
|
|
2025
Q1 | $299K | Sell |
245,092
-44,992
| -16% | -$63.1K | ﹤0.01% | 5562 |
|
|
2024
Q4 | $374K | Buy |
290,084
+44,004
| +18% | +$105K | ﹤0.01% | 5547 |
|
|
2024
Q3 | $677K | Buy |
246,080
+18,863
| +8% | +$46.3K | ﹤0.01% | 5254 |
|
|
2024
Q2 | $514K | Buy |
227,217
+42,526
| +23% | +$129K | ﹤0.01% | 5280 |
|
|
2024
Q1 | $441K | Sell |
184,691
-185,603
| -50% | -$351K | ﹤0.01% | 5369 |
|
|
2023
Q4 | $615K | Buy |
370,294
+185,535
| +100% | +$360K | ﹤0.01% | 5539 |
|
|
2023
Q3 | $355K | Sell |
184,759
-325
| -0.2% | -$535 | ﹤0.01% | 5318 |
|
|
2023
Q2 | $267K | Sell |
185,084
-3,245
| -2% | -$5.5K | ﹤0.01% | 5513 |
|
|
2023
Q1 | $395K | Buy |
188,329
+149,564
| +386% | +$242K | ﹤0.01% | 5390 |
|
|
2022
Q4 | $43.8K | Buy |
38,765
+1,218
| +3% | +$1.62K | ﹤0.01% | 6353 |
|
|
2022
Q3 | $61K | Sell |
37,547
-21,309
| -36% | -$39.8K | ﹤0.01% | 6317 |
|
|
2022
Q2 | $77K | Sell |
58,856
-4,653
| -7% | -$6.69K | ﹤0.01% | 6403 |
|
|
2022
Q1 | $102K | Sell |
63,509
-29,794
| -32% | -$57.7K | ﹤0.01% | 6294 |
|
|
2021
Q4 | $194K | Buy |
93,303
+43,335
| +87% | +$124K | ﹤0.01% | 6089 |
|
|
2021
Q3 | $195K | Buy |
49,968
+9,158
| +22% | +$31K | ﹤0.01% | 6011 |
|
|
2021
Q2 | $131K | Buy |
40,810
+14,450
| +55% | +$51.4K | ﹤0.01% | 6221 |
|
|
2021
Q1 | $57K | Sell |
26,360
-27,302
| -51% | -$61.2K | ﹤0.01% | 6295 |
|
|
2020
Q4 | $121K | Buy |
53,662
+22,083
| +70% | +$57.9K | ﹤0.01% | 5831 |
|
|
2020
Q3 | $85K | Sell |
31,579
-33,613
| -52% | -$94.1K | ﹤0.01% | 5505 |
|
|
2020
Q2 | $199K | Buy |
65,192
+9,681
| +17% | +$24.4K | ﹤0.01% | 5078 |
|
|
2020
Q1 | $109K | Sell |
55,511
-108,050
| -66% | -$263K | ﹤0.01% | 5152 |
|
|
2019
Q4 | $468K | Buy |
163,561
+86,147
| +111% | +$299K | ﹤0.01% | 4963 |
|
|
2019
Q3 | $284K | Buy |
77,414
+23,769
| +44% | +$85.9K | ﹤0.01% | 4957 |
|
|
2019
Q2 | $222K | Sell |
53,645
-5,332
| -9% | -$23.1K | ﹤0.01% | 4978 |
|
|
2019
Q1 | $301K | Sell |
58,977
-3,228
| -5% | -$15.5K | ﹤0.01% | 4840 |
|
|
2018
Q4 | $213K | Buy |
62,205
+4,518
| +8% | +$21.6K | ﹤0.01% | 5259 |
|
|
2018
Q3 | $346K | Sell |
57,687
-3,650
| -6% | -$20.1K | ﹤0.01% | 5193 |
|
|
2018
Q2 | $391K | Buy |
61,337
+17,077
| +39% | +$83.2K | ﹤0.01% | 5245 |
|
|
2018
Q1 | $210K | Buy |
44,260
+28,092
| +174% | +$131K | ﹤0.01% | 5447 |
|
|
2017
Q4 | $54K | Sell |
16,168
-87,268
| -84% | -$221K | ﹤0.01% | 5813 |
|
|
2017
Q3 | $220K | Sell |
103,436
-5,052
| -5% | -$10K | ﹤0.01% | 5313 |
|
|
2017
Q2 | $267K | Buy |
108,488
+19,005
| +21% | +$50.6K | ﹤0.01% | 5176 |
|
|
2017
Q1 | $206K | Buy |
89,483
+83,020
| +1,285% | +$125K | ﹤0.01% | 5315 |
|
|
2016
Q4 | $7K | Sell |
6,463
-158
| -2% | -$140 | ﹤0.01% | 6227 |
|
|
2016
Q3 | $7K | Sell |
6,621
-1,507
| -19% | -$2.68K | ﹤0.01% | 6180 |
|
|
2016
Q2 | $12K | Buy |
8,128
+2,220
| +38% | +$3.26K | ﹤0.01% | 6010 |
|
|
2016
Q1 | $8K | Sell |
5,908
-4,589
| -44% | -$6.16K | ﹤0.01% | 6179 |
|
|
2015
Q4 | $17K | Sell |
10,497
-3,813
| -27% | -$8.73K | ﹤0.01% | 6084 |
|
|
2015
Q3 | $34K | Sell |
14,310
-13,056
| -48% | -$30.8K | ﹤0.01% | 5866 |
|
|
2015
Q2 | $74K | Buy |
27,366
+7,422
| +37% | +$22.4K | ﹤0.01% | 5727 |
|
|
2015
Q1 | $67K | Sell |
19,944
-80,223
| -80% | -$287K | ﹤0.01% | 5681 |
|
|
2014
Q4 | $347K | Buy |
100,167
+74,132
| +285% | +$328K | ﹤0.01% | 4923 |
|
|
2014
Q3 | $130K | Sell |
26,035
-58,904
| -69% | -$459K | ﹤0.01% | 5354 |
|
|
2014
Q2 | $1.17M | Sell |
84,939
-7,007
| -8% | -$87.2K | ﹤0.01% | 3937 |
|
|
2014
Q1 | $1.41M | Buy |
91,946
+74,266
| +420% | +$1.06M | ﹤0.01% | 3722 |
|
|
2013
Q4 | $143K | Buy |
17,680
+3,056
| +21% | +$28.2K | ﹤0.01% | 5193 |
|
|
2013
Q3 | $146K | Buy |
+14,624
| New | +$98.7K | ﹤0.01% | 4994 |
|
Other funds holding GALT
WANY
Morgan Stanley's GALT Position: Q2 2026 in Review
Morgan Stanley reduced its Galectin Therapeutics (GALT) stake by 10% in Q2 2026, selling an estimated $28.3K and leaving 93,475 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #5612.
Morgan Stanley first reported a position in GALT in Q3 2013 and has held it in 52 quarters since. The position peaked at $1.41M in Q1 2014. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Morgan Stanley held 93,475 shares of Galectin Therapeutics worth $434K as of Q2 2026.
- Morgan Stanley sold 10,930 Galectin Therapeutics shares in Q2 2026, an estimated $28.3K.
- Galectin Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5612 holding.
- Morgan Stanley first reported a position in Galectin Therapeutics in Q3 2013 and has held it in 52 quarters since.
- Morgan Stanley's Galectin Therapeutics position peaked at $1.41M in Q1 2014.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.